Sanofi now covers seven major therapeutic areas: Sanofi’s CEO is Christopher A. Viehbacher, who has been in this position since 1st December 2008. Christopher is also a Sanofi board member and a ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

As the Q1 earnings season rolls on, investors are bracing for another high-stakes week with a lineup of heavyweights across ...